Methods for diagnosing mood disorders
AssigneeWyeth
InventorsXavier Zafar Khawaja, Jun Xu, Jinjun Liang
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the fields of neuroscience, proteomics and mood disorders. More particularly, the present invention relates to the identification of a group of proteins modulated in subjects with a mood disorder; methods for detecting or screening mRNA encoding these proteins and methods for diagnosing mood disorders.
Claims23
1-23. (canceled)
A method for monitoring the kinetics of an inhibitor of a monoamine re-uptake receptor in a rodent comprising the steps of:
- (a) administering to a plurality of rodents a monoamine re-uptake inhibitor or a placebo;
- (b) obtaining, at a desired time point, a hippocampus from one of the plurality of rodents administered the monoamine re-uptake inhibitor in step (a) and a hippocampus from one of the plurality of rodents administered a placebo in step (a);
- (c) determining the amount of one or more proteins in the hippocampus from step (b), wherein the one or more proteins are selected from the group of proteins set forth in Table 1, (d) repeating steps (b) and (c), wherein a range of desired time points are gathered from 0 days to about 36 days.
A method for monitoring the kinetics of an inhibitor of a monoamine re-uptake receptor in a recombinant cell comprising the steps of:
- (a) administering to a plurality of the recombinant cells a monoamine re-uptake inhibitor or a placebo;
- (b) obtaining, at a desired time point, a cell from one of the plurality of cells administered the monoamine re-uptake inhibitor in step (a) and a cell from one of the plurality of cells administered a placebo in step (a);
- (c) determining the amount of one or more proteins in the cell from step (b), wherein the one or more proteins are selected from the group of proteins set forth in Table 1, (d) repeating steps (b) and (c), wherein a range of desired time points are gathered from 0 days to about 36 days.
26-30. (canceled)
A method for assessing the biological activity of a monoamine reuptake inhibitor in a human subject comprising:
- (a) obtaining a biological sample from the subject, wherein the subject is administered a monoamine reuptake inhibitor;
- (b) applying the sample to an array comprising a plurality of protein-capture agents, wherein a protein-capture agent of said plurality of protein capture agents binds to a protein selected from the group of proteins set forth in Table 1;
- (c) measuring the amount of the protein bound to the protein-capture agent;
- and (d) comparing the amount in step (c) with an array standard, wherein higher levels of the protein in the subject relative to the standard indicates biological activity of the monoamine reuptake inhibitor.
33-42. (canceled)
A protein capture array comprising at least two protein capture agents immobilized on a substrate, wherein each of said at least two protein capture agents binds to a protein selected from the group of proteins set forth in Table 1.
Dependencies are inferred from the claim text.